- All
- #InspiredByLife
- Bioeconomy
- Biosimilars
- BREXIT
- Cell & Gene Therapies
- Circular Economy
- Climate Change
- COVID-19
- Factsheet
- Genome editing
- HEALTHCARE BIOTECH
- INDUSTRIAL BIOTECH
- Innovation
- Intellectual Property
- Interview
- Jobs & Growth
- NATIONAL ASSOCIATIONS
- News
- Other
- Patient Bio-Forum
- Position Paper
- Press release
- Public Procurement
- Regulatory Efficiency
- Report
- SME
- SME Platform
- WHAT IF
- White paper
29/04/2021
EuropaBio welcomes the in-depth opinion of the European Group on Ethics on the uses of genome editing and thanks the Group for raising the awareness of a technology which will enable the development of many solutions for healthy people and planet.
27/04/2021
EuropaBio welcomes the in-depth opinion of the European Group on Ethics on the uses of genome editing and thanks the Group for raising the awareness of a technology which will enable the development of many solutions for healthy people and planet.
28/05/2018
As an association that has manufacturers of both originator and biosimilar medicines as members, EuropaBio strongly doubts that the promises of today’s Commission proposal outweigh the risks of losing investment in new medicines.
03/03/2017
EuropaBio notes the adoption by the European Parliament of the report on EU options for improving patient access to medicines on 2 March 2017, in Brussels.
